Our results show that C9 and CsA inhibited the proliferation of EGFR-mutant NSCLC CSCs more sensitively than EGFR-wild-type NSCLC CSCs, indicating that CypA inhibitors exhibit more effective antiproliferative activity against CSCs derived from NSCLC cells with increased EGFR activity. This evidence concerns the gene PPIA and non-small cell lung carcinoma.